IMMUNIC, INC. (IMUX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US4525EP1011
IMMUNIC, INC. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -103.23 m USD |
| EBIT | -98.21 m USD |
| Net income | -97.17 m USD |
| Diluted EPS – continuing operations | -0.62 USD |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About IMMUNIC, INC.
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
More stocks
- Info-Tek (8183.TWO)
- Indonesia Fibreboard Industry PT (IFII.JK)
- Silla Co.Ltd (004970.KS)
- FLANIGANS ENTERPRISES INC (BDL)
- Heidelberg Pharma (HPHA.DE)
- Shanghai Jinjiang International Travel Co Ltd (900929.SS)
- GoPro, Inc. (GPRO)
- Hsin Ba Ba Corp (9906.TW)
- Canagold Resources Ltd (CCM.TO)
- RAC Electric Vehicles Inc. (2237.TWO)
- Joyce Corporation Ltd (JYC.AX)
- Data Communications Management Ltd (DCM.TO)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.